IL6 and Castleman disease: By forming a high-affinity complex with human interleukin-6 (IL-6) to prevent IL-6 from binding to soluble and membrane-bound IL-6 receptors, stuximab is used to treat Castleman’s disease, a type of lymphoproliferative disease [43].